Last reviewed · How we verify
Dihydroergocriptine (dihydroergocryptine)
Dihydroergocriptine (generic name: dihydroergocryptine) is a dihydroergocryptine drug. It is currently FDA-approved.
At a glance
| Generic name | dihydroergocryptine |
|---|---|
| Drug class | dihydroergocryptine |
| Target | 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 7 |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dihydroergocriptine CI brief — competitive landscape report
- Dihydroergocriptine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Dihydroergocriptine
What is Dihydroergocriptine?
Dihydroergocriptine (dihydroergocryptine) is a dihydroergocryptine drug.
What is the generic name of Dihydroergocriptine?
dihydroergocryptine is the generic (nonproprietary) name of Dihydroergocriptine.
What drug class is Dihydroergocriptine in?
Dihydroergocriptine belongs to the dihydroergocryptine class. See all dihydroergocryptine drugs at /class/dihydroergocryptine.
What development phase is Dihydroergocriptine in?
Dihydroergocriptine is FDA-approved (marketed).
What does Dihydroergocriptine target?
Dihydroergocriptine targets 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 7 and is a dihydroergocryptine.
Related
- Drug class: All dihydroergocryptine drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 7
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing